Search Results - andrew+gewirtz

3 Results Sort By:
Powerful Formulation for Respiratory Infection Prevention and Treatment
Description This technology is a set of innovative pharmaceutical formulations that utilize metabolites derived from specific gut microbiota to prevent respiratory infections and enhance immune health. Formulations are available for both oral and intranasal administration, offering flexibility and ease of use. By strengthening the immune system's...
Published: 5/14/2025   |   Inventor(s): Andrew Gewirtz, Vu Le Ngo
Keywords(s):  
Category(s): Therapeutics
Biologic Therapeutic for Graft-versus-Host Disease (GvHD)
Application Biotherapeutic activation of toll-like receptor 5 (TLR5) to treat graft-versus-host disease (GvHD). Key Benefits Administration of flagellin reduces both acute and chronic GvHD. Contrary to immunosuppressive drugs, flagellin enhances immunity and protects patients from opportunistic infections. Market Summary Transplant recipients...
Published: 3/6/2025   |   Inventor(s): Mohammad Hossain, Andrew Gewirtz, John Roback, Edmund K. Waller
Keywords(s): Biologics, Immunology and Inflammation Treatments, Microbiology and Infectious Disease Treatments
Category(s): TechPub Algolia > Drug Discovery, TechPub Algolia > Therapeutics
Flagellin Fragments as Potential Treatment for Chronic Viral Infections
Application The use of flagellin and its fragments for treating chronic viral infections (CVI) including infections caused by HIV, Hepatitis viruses, Rotaviruses and Cytomegalovirus. Key Benefits Administration of Toll-like receptor-5 (TLR5) agonist - flagellin resolves a chronic rotaviral infection in mice. Flagellin protects mice from rotavirus...
Published: 7/22/2025   |   Inventor(s): Andrew Gewirtz, Benyue Zhang
Keywords(s): COVID19, Microbiology and Infectious Disease Treatments
Category(s): TechPub Algolia > Therapeutics